for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Koninklijke DSM N.V.

DSMN.AS

Latest Trade

107.10EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

68.00

 - 

117.15

As of on the Euronext Amsterdam Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
107.10
Open
--
Volume
--
3M AVG Volume
12.39
Today's High
--
Today's Low
--
52 Week High
117.15
52 Week Low
68.00
Shares Out (MIL)
175.65
Market Cap (MIL)
19,430.62
Forward P/E
21.51
Dividend (Yield %)
2.15

Next Event

Q3 2019 Koninklijke DSM NV Earnings Release

Latest Developments

More

DSM Completes Creation Of Vitamin E Joint Venture With Nenter

DSM Q2 Adjusted EBITDA Beats Company-Compiled Poll

DSM Announces Early Redemption Of The 300 Million Euros Bond Maturing November 13, 2019

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Koninklijke DSM N.V.

Koninklijke DSM N.V. (Royal DSM) is a global science-based company, engaged in offering health, nutrition and materials. The Company's segments include Nutrition, Performance Materials, Innovation Center and Corporate Activities. Its Nutrition segment includes DSM Nutritional Products and DSM Food Specialties. Its Performance Materials segment consists of DSM Engineering Plastics, DSM Dyneema, and DSM Resins and Functional Materials. Its Innovation Center segment serves as an enabler and accelerator of innovation within DSM, as well as providing support to the clusters. Its Corporate Activities segment includes various holding companies and corporate overheads. The Corporate Activities segment includes Sitech Services. The Company delivers its solutions in global markets, such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials.

Industry

Chemical Manufacturing

Contact Info

Het Overloon 1

+31.45.5788111

https://www.dsm.com/

Executive Leadership

Robert J. Routs

Independent Chairman of the Supervisory Board

Feike Sijbesma

Chief Executive Officer and Chairman of the Managing Board

Geraldine Matchett

Chief Financial Officer, Member of the Managing Board

Dimitri de Vreeze

Member of the Managing Board

Victoria F. Haynes

Independent Member of the Supervisory Board

Key Stats

2.35 mean rating - 26 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

7.9K

2017

8.6K

2018

9.3K

2019(E)

9.2K
EPS (EUR)

2016

2.900

2017

3.920

2018

5.840

2019(E)

4.977
Price To Earnings (TTM)
22.46
Price To Sales (TTM)
2.15
Price To Book (MRQ)
2.42
Price To Cash Flow (TTM)
15.54
Total Debt To Equity (MRQ)
36.86
LT Debt To Equity (MRQ)
31.24
Return on Investment (TTM)
6.48
Return on Equity (TTM)
5.25

Latest News

DSM sets up vitamin E joint venture with China's Nenter

DSM NV, the Dutch nutrition company, said on Tuesday it would set up a joint venture with Chinese biochemicals company Nenter & Co. to manufacture vitamin E, paying Nenter 135 million euros ($154.45 million) to acquire its facilities in China.

UPDATE 1-DSM Q3 core profit rises 11 pct on higher vitamin prices

Dutch speciality chemicals company DSM on Wednesday beat analyst expectations with an 11-percent rise in third-quarter core profit, to 406 million euros ($460.4 million), helped by elevated vitamin prices and higher sales.

DSM Q3 core profit rises 11 pct on higher vitamin prices

Dutch speciality chemicals company DSM on Wednesday beat analyst expectations with an 11-percent rise in third-quarter core profit, to 406 million euros ($460.4 million), helped by elevated vitamin prices and higher sales.

UPDATE 1-DSM's Q2 core profit surges 35 pct on vitamin boost; confirms outlook

Dutch speciality chemicals company DSM on Wednesday said second-quarter core profit surged 35 percent to 508 million euros ($593.2 million), boosted by exceptionally high vitamin prices and cost cuts.

DSM's Q2 core profit rises 35 pct on vitamin boost

Dutch specialty chemicals company DSM on Wednesday said second-quarter core profit rose 35 percent to 508 million euros ($593.2 million), helped by elevated vitamin prices and cost cuts.

UPDATE 1-Dutch chemical firm DSM's Q4 profit beats expectations

Dutch speciality chemicals company DSM on Wednesday reported a higher-than-expected 14 percent rise in fourth-quarter core profit, to 359 million euros ($444.3 million), as sales of its food ingredients and basic materials continued to grow.

Dutch chemical firm DSM's Q4 profit beats expectations

Dutch speciality chemicals company DSM on Wednesday reported a higher-than-expected 14 percent rise in fourth-quarter core profit, to 359 million euros ($444.3 million), as sales of its food ingredients and basic materials continued to grow.

BRIEF-DSM Announces DSM-Niaga Research Collaboration With Ecor

* PRELIMINARY RESULTS LED TO FURTHER INVESTIGATING OF APPLICATIONS AND WILL LEAD TO NEW FULLY RECYCLABLE PRODUCTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-DSM acquires Brazilian production facility from Amyris

* DSM expands strategic alliance with Amyris and acquires Brazilian production facility from Amyris

BRIEF-DSM signs technology partnership agreement with Toyota Motorsport GmbH

* SIGNS TECHNOLOGY PARTNERSHIP AGREEMENT WITH TOYOTA MOTORSPORT GMBH

UPDATE 1-Dutch firm DSM reports better-than-expected rise in Q3 profit

Dutch speciality chemicals company DSM on Thursday said higher sales and tighter cost controls helped third-quarter core profit rise 13 percent, to 365 million euros ($425.3 million).

Dutch firm DSM reports better-than-expected rise in Q3 profit

Dutch speciality chemicals company DSM on Thursday said higher sales and tighter cost controls helped third-quarter core profit rise 13 percent, to 365 million euros ($425.3 million).

BRIEF-Amyris Inc enters into agreement with Koninklijke DSM N.V.

* Amyris enters into product development and production agreement with Royal DSM for human nutrition ingredient

BRIEF-Amyris enters into second major product development with Royal DSM

* Amyris Inc enters into second major product development and production agreement with Royal DSM

BRIEF-Amyris says second tranche of $50 mln in a private placement days is being led by a $25-mln investment from Koninklijke​

* Amyris announces agreements for $50 million in second tranche of equity financing, exceeding previous target of $95 million

UPDATE 2-DSM raises 2017 profit forecasts, shares jump

Dutch speciality chemicals company DSM raised its profit forecast for 2017 on Tuesday after higher sales and tighter cost controls helped it report a better than expected 15 percent rise in second-quarter earnings.

BRIEF-Aerie Pharmaceuticals enters into collaboration agreement with DSM

* Aerie Pharmaceuticals enters into collaboration agreement with DSM focused on technology to potentially deliver Aerie compounds to treat retinal diseases such as wet AMD

BRIEF-Amyris enters into first product development, production agreement with Royal DSM

* Amyris enters into first product development and production agreement with Royal DSM for food and nutrition molecule

BRIEF-Beijing WKW Automotive Parts plans to buy stake in DSM Green Power Ltd

* Says it plans to buy 23 percent stake in DSM Green Power Ltd for 115 million yuan ($16.90 million)

BRIEF-Alpiq and DSM make secondary balancing power available to Swissgrid

* ALPIQ AND THE FINE CHEMICALS MANUFACTURER DSM MAKE SECONDARY BALANCING POWER AVAILABLE TO SWISSGRID Source text - http://bit.ly/2rpwdYk Further company coverage: (Gdynia Newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up